Clinical trials: Statin Dose
Hypercholesterolemia
Efficacy and Safety Study of Pitavastatin Versus Atorvastatin to Treat Hypercholesterolemia
Statin is an effective drug to treat hyperlipidemia (hypercholesterolemia), and it rarely leads to hepatic damage to the patients with hepatic disorder. For these patients, intensive monitoring is required.
- Trial name
- PITCH (NCT01166633)
- Testing
- pitavastatin, atorvastatin
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- JW Pharmaceutical
Tuberculosis, Pulmonary Tuberculosis
StAT-TB (Statin Adjunctive Therapy for TB): A Phase 2b Dose-finding Study of Pravastatin in Adults With Tuberculosis
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of pravastatin adjunctive therapy when combined with the standard tuberculosis (TB) treatment regimen in adults with TB.
- Trial name
- NCT03882177
- Testing
- Pravastatin, Rifafour, Vitamin B6
- Where
- South Africa
- Volunteers
- 16 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Stable Angina
Atorvastatin and Clopidogrel HIgh DOse in Stable Patients With Residual High Platelet Activity
The purpose of this study is to evaluate if high-dose (80mg/day) atorvastatin might exert an adjunctive anti-platelet effect compared to high-dose clopidogrel (150mg/day) in stable patients with high on-treatment reactivity…
- Trial name
- ACHIDO (NCT01335048)
- Testing
- atorvastatin and clopidogrel, Clopidogrel
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Ospedale Misericordia e Dolce
Dyslipidemia
Safety Study of BMS-823778 in Subjects With Hypercholesterolemia
The purpose of this study is to assess the safety, tolerability and pharmacodynamic effects on LDL cholesterol (LDL-C)
- Trial name
- NCT01112423
- Testing
- BMS-823778
- Where
- 12 sites in United States, Australia and 1 more
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb
Dyslipidemia
The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)
This study will investigate the effect of MK0859 on lipoprotein metabolism in patients with dyslipidemia already on statin therapy.
- Trial name
- NCT00990808
- Testing
- anacetrapib, Comparator: atorvastatin
- Volunteers
- 46 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypercholesterolemia, LDL Cholesterol
Safety, Pharmacokinetics and Pharmacodynamics of LGT209 in Healthy Volunteers With Elevated Cholesterol and in Hypercholesterolemic Patients Treated With Statins
This study is designed to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of LGT209 in hypercholesterolemic patients taking common statin medications and in healthy volunteers.
- Trial name
- NCT01859455
- Testing
- LGT209 50 mg, LGT209 300 mg, Statins (atorvastatin or simvastatin)
- Where
- 2 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Coronary Artery
Combination Effects of High-dose Statin and Trimetazidine on Patients With Aspirin Mono Antiplatelet Therapy 12-months After Coronary Artery Bypass Surgery
Trimetazidine is a metabolic agent without any negative inotropic or vasodilatory properties. In addition, previous reports showed that trimetazidine was effective in reducing intracoronary platelet aggregation and preventing…
- Trial name
- NCT01857921
- Testing
- Pravastatin 20mg/day for 12 months after randomization, Atorvastatin 40 mg and trimetazidine MR 70 mg/day for 12 months after randomization
- Where
- South Korea
- Volunteers
- 290 people
- Sponsor
- Yonsei University
Squamous Cell Carcinoma, Non-Small Cell Lung Cancer
Phase I Study of a Statin + Erlotinib for Advanced Solid Malignancies With Focus on Squamous Cell Carcinomas and NSCLC
The purpose of this study is to determine the recommended phase II dose (RP2D) of rosuvastatin that can be given in combination with standard erlotinib treatment in patients with advanced incurable squamous cell cancer and NSCLC.
- Trial name
- NCT00966472
- Testing
- Erlotinib + Rosuvastatin
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- Ottawa Hospital Research Institute
Saphenous Vein Graft Disease
Aggressive Cholesterol Therapy to Inhibit Vein Graft Events After CABG (ACTIVE Trial)
During coronary artery bypass graft surgery (CABG), saphenous vein from the leg is used to bypass the atherosclerotic blockages in the arteries of the heart.
- Trial name
- ACTIVE (NCT01528709)
- Testing
- Atorvastatin 80 mg daily, Atorvastatin 10 mg daily
- Where
- 2 sites in United States, Canada
- Volunteers
- 173 people
- Sponsor
- Boca Raton Regional Hospital
Thrombosis, Prevention
Re-STOP DVT: Reload of High Dose Atorvastatin for Preventing Deep Vein Thrombosis in Statin Users
Reload of high dose statin may have potential for preventing deep vein thrombosis (DVT) in patients on statin undergoing total knee replacement arthroplasty.
- Conditions
- Thrombosis, Prevention, Surgery
- Trial name
- Re-STOP DVT (NCT01063426)
- Testing
- High dose Atorvastatin+enoxaparin, Enoxaparin
- Where
- South Korea
- Volunteers
- 180 people
- Sponsor
- Hallym University Medical Center
Statin Dose
Effective Dose of Statin Post PCI
In this study post coronary stenting patients, were enrolled to receive moderate dose versus high dose statin for 1 year, and the result of major adverse cardiovascular events were recorded
- Trial name
- NCT04923152
- Testing
- moderate statin dose, high dose statin
- Where
- Iran
- Volunteers
- 582 people
- Sponsor
- Shiraz University of Medical Sciences
Hypercholesterolemia, Dyslipidemia
A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins
PF-04950615 is a new investigational hypercholesterolemic agent that is being tested in this study to evaluate if it can lower LDL cholesterol.
- Trial name
- NCT01350141
- Testing
- PF-04950615 (RN316)
- Where
- 35 sites in United States, Canada
- Volunteers
- 46 people
- Sponsor
- Pfizer
Hypercholesterolemia
Safety, Tolerability, PK and PD of LGT209 in Healthy Volunteers and Patients With Hypercholesterolemia
This study is designed to measure the effects of LGT209 when given intravenously to patients with high cholesterol who are on stable doses of statin medications, and to healthy subjects with elevated cholesterol
- Trial name
- NCT01979601
- Testing
- LGT209
- Where
- 2 sites in United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Atherosclerosis
EASEGO Study: Doubling of Atorvastatin/Simvastatin or INEGY in Patients With Hypercholesterolemia and Coronary Artery Disease(CAD)(0653A-089)
In patients with coronary artery disease and a LDL-C level between 2.5 mmol/L and 5.0 mmol/L on a stable (> 4 weeks) statin starting dose (simvastatin 20 mg or atorvastatin 10 mg), investigate what the LCL-C lowering efficacy is…
- Trial name
- NCT00166530
- Testing
- ezetimibe (+) simvastatin, simvastatin, atorvastatin
- Volunteers
- 367 people
- Sponsor
- Organon and Co
Stable Angina
Antiplatelet and Anti-inflammatory Effects of Statins and Ezetimibe
Among patients with stable coronary artery disease (CAD), it is not clear if the pleiotropic effects of cholesterol reduction differ between high-dose simvastatin alone and combined ezetimibe/simvastatin.
- Trial name
- NCT00474123
- Testing
- Simvastatin 80 mg/day for 6 weeks, Ezetimibe 10 mg / Simvastatin 20 mg
- Where
- Brazil
- Volunteers
- 78 people
- Sponsor
- University of Sao Paulo
Hypercholesterolemia
Comparison of the Effect of Vytorin 10/80 Tablet Split Into 4 and Simvastatin 20 Milligrams on Low-density Lipoprotein (LDL) Cholesterol
The purpose of this study is to compare the efficacy of a Vytorin 10/80 tablet, an approved agent for the treatment of elevated LDL cholesterol which combines the cholesterol absorption inhibitor Ezetimibe 10 mg and simvastatin…
- Trial name
- NCT00762164
- Testing
- Vytorin, Simvastatin
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Bronx VA Medical Center
Atorvastatin
Citrulline Efficacy to Improve Carbohydrate Metabolism Abnormalities in the Patient Treated With High Doses of Statin
Hypercholesterolemia is a major cardiovascular risk factor. Statins are the first-line drug treatment for hypercholesterolemia and have been shown to be effective in both primary and secondary prevention of cardiovascular…
- Trial name
- STATIMPROVE (NCT03596684)
- Testing
- citrulline supplementation, glucose tolerance test
- Where
- France
- Volunteers
- 2 people
- Sponsor
- Hospices Civils de Lyon
Multiple Myeloma
The Effect of High Dose Simvastatine on Multiple Myeloma
The purpose of the study is to evaluate the effect of high doses of Simvastatine on bone metabolisme and biochemical markers of disease in Multiple Myeloma
- Trial name
- NCT00281476
- Testing
- Simvastatine
- Volunteers
- 10 people
- Sponsor
- Vejle Hospital
Subarachnoid Hemorrhage
High-dose Simvastatin for Aneurysmal Subarachnoid Haemorrhage
Experimental evidences supported the benefit of Simvastatin in subarachnoid haemorrhage. Moreover, Simvastatin is a potent agent in achieving low-density lipoprotein (LDL) reduction with a proven safety profile.
- Trial name
- HDS-SAH (NCT01077206)
- Testing
- Simvastatin
- Where
- China
- Volunteers
- 255 people
- Sponsor
- Chinese University of Hong Kong
Medication Adherence
Reducing African-American CVD Disparities Intervention Optimization (RADIO) Individuals on Statins
The purpose of this project is to identify the minimum effective dose (MED) of a multi-component behavioral change intervention required to increase levels of medication adherence among Black and African American individuals on…
- Trial name
- RADIO (NCT05954000)
- Testing
- 5 Behavioral Change Techniques
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Northwell Health